カテゴリー： 世界, 医療/バイオ, visiongain

世界の無菌注射剤CMO（受託製造アウトソーシング）市場2022年～2032年

【英語タイトル】Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Report 2022-2032 : Forecasts by Molecule Type (Small Molecule, Large Molecule), by Type (Monoclonal Antibodies (mAbs), Cytokines, Insulin, Peptide Hormones, Vaccines, Immunoglobulins, Blood Factors, Peptide Antibiotics, Others), by Application (Cancer, Diabetes, Cardiovascular Diseases, CNS, Infectious, Others), by Container Type (Bottles, Ampoules, Vials, Pre-filled Syringes, Bags), by Route of Administration (Subcutaneous (SC), Intravenous (IV), Intramuscular (IM), Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis

visiongainが出版した調査資料（VGA23FB006）・商品コード：VGA23FB006
・発行会社（調査会社）：visiongain
・発行日：2022年12月16日
・ページ数：357
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後24時間以内）
・調査対象地域：グローバル
・産業分野：医薬品
◆販売価格オプション（消費税別）
Sigle User（1名様閲覧用、1年間、印刷不可）GBP3,950 ⇒換算￥750,500見積依頼/購入/質問フォーム
Enterprise（法人閲覧用、1年間、印刷可）GBP6,950 ⇒換算￥1,320,500見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

Visiongain社の本調査レポートでは、世界の無菌注射剤CMO（受託製造アウトソーシング）市場規模が2032年までに年平均9.10%で成長すると予測しています。本レポートは、無菌注射剤CMO（受託製造アウトソーシング）の世界市場を徹底調査し、レポート概要、エグゼクティブサマリー、市場動向、分子タイプ別（低分子、高分子）分析、種類別（モノクローナル抗体 (mAb)、サイトカイン、インスリン、ペプチドホルモン、その他）分析、用途別（癌、糖尿病、心血管疾患、中枢神経系、その他）分析、容器種類別（ボトル、アンプル、バイアル、プレフィルドシリンジ、バッグ）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況、企業情報などの内容を作成しました。本書には、Adare Pharma Solutions、Aenova Group、Almac Group、Avara Pharmaceutical Services, Inc.、Baxter International Inc.、Boehringer Ingelheim International GmbH、Catalent, Inc.、CordenPharma、Eli Lilly and Company、Evonik Industries AG、F. Hoffmann-La Roche Ltdなどの企業情報が含まれています。
・レポート概要
・エグゼクティブサマリー
・市場動向
・世界の無菌注射剤CMO（受託製造アウトソーシング）市場規模：分子タイプ別
- 低分子無菌注射剤CMOの市場規模
- 高分子無菌注射剤CMOの市場規模
・世界の無菌注射剤CMO（受託製造アウトソーシング）市場規模：種類別
- モノクローナル抗体 (mAb)の市場規模
- サイトカインの市場規模
- インスリンの市場規模
- ペプチドホルモンの市場規模
- その他種類の市場規模
・世界の無菌注射剤CMO（受託製造アウトソーシング）市場規模：用途別
- 癌における市場規模
- 糖尿病における市場規模
- 心血管疾患における市場規模
- 中枢神経系における市場規模
- その他用途における市場規模
・世界の無菌注射剤CMO（受託製造アウトソーシング）市場規模：容器種類別
- ボトル入り無菌注射剤の市場規模
- アンプル入り無菌注射剤の市場規模
- バイアル無菌注射剤の市場規模
- プレフィルドシリンジ無菌注射剤の市場規模
- バッグ入り無菌注射剤の市場規模
・世界の無菌注射剤CMO（受託製造アウトソーシング）市場規模：地域別
- 北米の無菌注射剤CMO（受託製造アウトソーシング）市場規模
- ヨーロッパの無菌注射剤CMO（受託製造アウトソーシング）市場規模
- アジア太平洋の無菌注射剤CMO（受託製造アウトソーシング）市場規模
- 中南米の無菌注射剤CMO（受託製造アウトソーシング）市場規模
- 中東・アフリカの無菌注射剤CMO（受託製造アウトソーシング）市場規模
・競争状況
・企業情報

The Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Rising Demand for Outsourcing Drug Manufacturing by Pharmaceutical Companies to Boost Market Growth
Over the last few decades, contract manufacturing organisations (CMOs) have evolved as a viable alternative to pharmaceutical businesses’ in-house research and production departments. Contract manufacturing organisations (CMOs) are proven to be a successful business model as they become more integrated into pharmaceutical firms’ value chains. Despite the fact that the sector as a whole is expanding, many CMOs are encountering new obstacles. As a result of growing expenses, constantly improving technology, and a surge in mergers and acquisitions, competition in this sector has intensified. As a result of these considerations, organisations must decide what actions they might take to defend or improve their position.

Manufacturing costs are much lower in the Asia-Pacific area than in North America and Europe, and favourable laws are fuelling the rise of the CMO business. Despite the fact that API manufacturing services have mostly shifted to China and India, the United States remains the major site for pharmaceutical development outsourcing. Several reasons contribute to this predicament, including the abundance of funding and the concentration of pharmaceutical research hubs in universities. Pharmaceutical development in poor countries is also unfavourable owing to quality difficulties, logistical constraints, and legal challenges.

Market Growth is Hindered by Growing Competition from Small Manufacturers
The market’s discontinuance is considered in the perspective of the whole evaluation process for product lifespan and market viability. Drug discontinuation is defined as authorised products that are removed from the market or withdrawn for reasons other than safety or efficacy and are never again discontinued, marketed, exported, or used in the military. The possibility for a pharmaceutical corporation to pull a medicine from the market can have serious effects, including financial losses, loss of goodwill, and disrupted therapeutic research.

The consumer product literature contains well-developed dominating pricing methods, particularly skimming and penetration pricing. Pharmaceutical items use the same market-dynamic pricing mechanisms as other products. According to the current market study, the primary factor determining a product’s pricing is a larger therapeutic benefit. The greater the clinical benefit over previously accessible medications on the market, the higher the initial price of the product. If the sterile injectables medication product’s life cycle was not extended, this incident might result in significant losses for the corporation and, finally, product termination.

What Questions Should You Ask before Buying a Market Research Report?
• How is the CMO of Sterile Injectable Drugs market evolving?
• What is driving and restraining the CMO of Sterile Injectable Drugs market?
• How will each CMO of Sterile Injectable Drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
• How will the market shares for each CMO of Sterile Injectable Drugs submarket develop from 2022 to 2032?
• What will be the main driver for the overall market from 2022 to 2032?
• Will leading CMO of Sterile Injectable Drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
• Who are the leading players and what are their prospects over the forecast period?
• What are the CMO of Sterile Injectable Drugs projects for these leading companies?
• How will the industry evolve during the period between 2022 and 2032? What are the implications of CMO of Sterile Injectable Drugs projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the CMO of Sterile Injectable Drugs market?
• Where is the CMO of Sterile Injectable Drugs market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the CMO of Sterile Injectable Drugs market today, and over the next 10 years:
• Our 357-page report provides 116 tables and 175 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the CMO of Sterile Injectable Drugs market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2032 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising CMO of Sterile Injectable Drugs prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Molecule Type
• Small Molecule
• Large Molecule

Type
• Monoclonal Antibodies (mAbs)
• Cytokines
• Insulin
• Peptide Hormones
• Vaccines
• Immunoglobulins
• Blood Factors
• Peptide Antibiotics
• Others

Application
• Cancer
• Diabetes
• Cardiovascular diseases
• CNS
• Infectious
• Others

Container Type
• Bottles
• Ampoules
• Vials
• Prefilled syringes
• Bags

Route of Administration
• Subcutaneous (SC)
• Intravenous (IV)
• Intramuscular (IM)
• Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 18 leading national markets:

North America
• U.S.
• Canada

Europe
• Germany
• UK
• France
• Spain
• Italy
• Russia
• Rest of Europe

Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Rest of Latin America

MEA
• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, 2022 to 2032, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
• Adare Pharma Solutions
• Aenova Group
• Almac Group
• Avara Pharmaceutical Services, Inc.
• Baxter International Inc.
• Boehringer Ingelheim International GmbH
• Catalent, Inc.
• CordenPharma
• Eli Lilly and Company
• Evonik Industries AG
• F. Hoffmann-La Roche Ltd
• FAMAR Health Care Services
• Fresenius Kabi Ag
• Grifols SA
• Hikma Pharmaceuticals PLC
• Jubilant Pharmova Limited
• Lonza
• Nexus Pharmaceuticals, Inc.
• Patheon, Inc. (Thermo Fischer)
• Pfizer CentreOne
• Recipharm AB
• Siegfried Holding AG

Overall world revenue for Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, 2022 to 2032 in terms of value the market will surpass US$22,300.0 million in 2023, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, 2022 to 2032 report help you?
In summary, our 370+ page report provides you with the following knowledge:

• Revenue forecasts to 2032 for Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, 2022 to 2032 Market, with forecasts for molecule type, type, application, container type, and route of administration, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2032 for five regional and 18 key national markets – See forecasts for the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, 2022 to 2032 market in North America, Europe, Asia-Pacific, LA, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles for 22 of the major companies involved in the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, 2022 to 2032.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

1. Report Overview
1.1 Objectives of the Study
1.2 Introduction to CMO of Sterile Injectable Drugs Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Reports
1.10 About

2 Executive Summary

3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Growing Focus on Development to Treat Cancer
3.2.1.2 Rising Prevalence of Chronic Diseases
3.2.1.3 Rapid FDA Approvals of Sterile Injectable Drugs to Fuel Market Growth
3.2.1.4 As Manufacturers Invest in New Manufacturing Facilities, The Demand for Sterile Injectables is Expected to Rise
3.2.1.5 Increasing Demand for Biologicals is Expected to Drive the Demand
3.2.2 Market Restraining Factors
3.2.2.1 Growing Competition from Small Manufacturers
3.2.2.2 High Operational Costs
3.2.2.3 Inadequate Healthcare Infrastructure Across Developing Economies Challenging Market Growth
3.2.3 Market Opportunities
3.2.3.1 Prefilled Syringes to Offer Lucrative Growth Prospects
3.2.3.2 Growing Investments
3.2.3.3 Expanding Clinical Trial Opportunities in the Asia Pacific Region
3.2.4 Market Challenges
3.2.4.1 Disruption of Clinical Trials Due to Pandemic Breakout
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Supplier Power
3.4.2 Buyer Power
3.4.3 Competitive Rivalry
3.4.4 Threat from Substitutes
3.4.5 Threat of New Entrants
3.5 PEST Analysis
3.5.1 Political Factors Impacting CMO of Sterile Injectable Drugs Market
3.5.2 Economic Factors Impacting CMO of Sterile Injectable Drugs Market
3.5.3 Social Factors Impacting CMO of Sterile Injectable Drugs Market
3.5.4 Technological Factors Impacting CMO of Sterile Injectable Drugs Market

4 CMO of Sterile Injectable Drugs Market Analysis by Molecule Type
4.1 Key Findings
4.2 Molecule Type Segment: Market Attractiveness Index
4.3 CMO of Sterile Injectable Drugs Market Share by Molecule Type, 2022 & 2032
4.4 Small Molecule
4.5 Large Molecule
4.6 CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Molecule Type

5 CMO of Sterile Injectable Drugs Market Analysis by Type
5.1 Key Findings
5.2 Type Segment: Market Attractiveness Index
5.3 CMO of Sterile Injectable Drugs Market Share by Type, 2022 & 2032
5.4 Monoclonal Antibodies (mAbs)
5.5 Cytokines
5.6 Insulin
5.7 Peptide Hormones
5.8 Vaccines
5.9 Immunoglobulins
5.10 Blood Factor
5.11 Peptide Antibiotics
5.12 Others
5.13 CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Type

6 CMO of Sterile Injectable Drugs Market Analysis by Application
6.1 Key Findings
6.2 Application Segment: Market Attractiveness Index
6.3 CMO of Sterile Injectable Drugs Market Share by Application, 2022 & 2032
6.4 Cancer
6.5 Diabetes
6.6 Cardiovascular Diseases
6.7 CNS
6.8 Infectious
6.9 Others
6.10 CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Application

7 CMO of Sterile Injectable Drugs Market Analysis by Container Type
7.1 Key Findings
7.2 Container Type Segment: Market Attractiveness Index
7.3 CMO of Sterile Injectable Drugs Market Share by Container Type, 2022 & 2032
7.4 Bottles
7.5 Ampoules
7.6 Vials
7.7 Prefilled Syringes
7.8 Bags
7.9 CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Container Type

8 CMO of Sterile Injectable Drugs Market Analysis by Route of Administration
8.1 Key Findings
8.2 Route of Administration Segment: Market Attractiveness Index
8.3 CMO of Sterile Injectable Drugs Market Share by Route of Administration, 2022 & 2032
8.4 Subcutaneous
8.5 Intravenous
8.6 Intramuscular
8.7 Others
8.8 CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Route of Administration

9 CMO of Sterile Injectable Drugs Market Analysis by Service
9.1 Key Findings
9.2 Service Segment: Market Attractiveness Index
9.3 CMO of Sterile Injectable Drugs Market Share by Service, 2022 & 2032
9.4 Bioanalytical Testing
9.5 Method Development & Validation
9.6 Stability Testing
9.7 Others
9.8 CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Service

10 CMO of Sterile Injectable Drugs Market Analysis by Region
10.1 Key Findings
10.2 Regional Market Size Estimation and Forecast

11 North America CMO of Sterile Injectable Drugs Market Analysis
11.1 Key Findings
11.2 North America CMO of Sterile Injectable Drugs Market Attractiveness Index
11.3 North America CMO of Sterile Injectable Drugs Market by Country, 2022, 2027 & 2032 (US$ mn)
11.4 North America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Country
11.5 North America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Molecule Type
11.6 North America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Type
11.7 North America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Application
11.8 North America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Container Type
11.9 North America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Route of Administration
11.10 North America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Service
11.11 U.S.
11.12 Canada

12 Europe CMO of Sterile Injectable Drugs Market Analysis
12.1 Key Findings
12.2 Europe CMO of Sterile Injectable Drugs Market Attractiveness Index
12.3 Europe CMO of Sterile Injectable Drugs Market by Country, 2022, 2027 & 2032 (US$ mn)
12.4 Europe CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Country
12.5 Europe CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Molecule Type
12.6 Europe CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Type
12.7 Europe CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Application
12.8 Europe CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Container Type
12.9 Europe CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Route of Administration
12.10 Europe CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Service
12.11 Germany
12.12 U.K.
12.13 France
12.14 Italy
12.15 Spain
12.16 Russia
12.17 Rest of Europe

13 Asia Pacific CMO of Sterile Injectable Drugs Market Analysis
13.1 Key Findings
13.2 Asia Pacific CMO of Sterile Injectable Drugs Market Attractiveness Index
13.3 Asia Pacific CMO of Sterile Injectable Drugs Market by Country, 2022, 2027 & 2032 (US$ mn)
13.4 Asia Pacific CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Country
13.5 Asia Pacific CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Molecule Type
13.6 Asia Pacific CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Type
13.7 Asia Pacific CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Application
13.8 Asia Pacific CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Container Type
13.9 Asia Pacific CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Route of Administration
13.10 Asia Pacific CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Service
13.11 China
13.12 Japan
13.13 India
13.14 Australia
13.15 South-East Asia
13.16 Rest of Asia Pacific

14 Latin America CMO of Sterile Injectable Drugs Market Analysis
14.1 Key Findings
14.2 Latin America CMO of Sterile Injectable Drugs Market Attractiveness Index
14.3 Latin America CMO of Sterile Injectable Drugs Market by Country, 2022, 2027 & 2032 (US$ mn)
14.4 Latin America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Country
14.5 Latin America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Molecule Type
14.6 Latin America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Type
14.7 Latin America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Application
14.8 Latin America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Container Type
14.9 Latin America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Route of Administration
14.10 Latin America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Service
14.11 Brazil
14.12 Mexico
14.13 Rest of Latin America

15 Middle East & Africa CMO of Sterile Injectable Drugs Market Analysis
15.1 Key Findings
15.2 Middle East & Africa CMO of Sterile Injectable Drugs Market Attractiveness Index
15.3 Middle East & Africa CMO of Sterile Injectable Drugs Market by Country, 2022, 2027 & 2032 (US$ mn)
15.4 Middle East & Africa CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Country
15.5 Middle East & Africa CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Molecule Type
15.6 Middle East & Africa CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Type
15.7 Middle East & Africa CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Application
15.8 Middle East & Africa CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Container Type
15.9 Middle East & Africa CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Route of Administration
15.10 Middle East & Africa CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Service
15.11 GCC
15.12 South Africa
15.13 Rest of Middle East & Africa

16 Competitive Landscape
16.1 Company Share Analysis
16.2 Key Business Strategy Analysis

17 Company Profiles
17.1 Aenova Group
17.1.1 Company Snapshot
17.1.2 Company Overview
17.1.3 Product Benchmarking
17.1.4 Strategic Outlook
17.2 Almac Group
17.2.1 Company Snapshot
17.2.2 Company Overview
17.2.3 Product Benchmarking
17.2.4 Strategic Outlook
17.3 Baxter International Inc.
17.3.1 Company Snapshot
17.3.2 Company Overview
17.3.3 Financial Analysis
17.3.3.1 Net Revenue, 2017-2021
17.3.3.2 Regional Revenue/Market Shares, 2020
17.3.4 Product Benchmarking
17.3.5 Strategic Outlook
17.4 Boehringer Ingelheim International GmbH
17.4.1 Company Snapshot
17.4.2 Company Overview
17.4.3 Financial Analysis
17.4.3.1 Net Revenue, 2017-2021
17.4.3.2 Regional Revenue/Market Shares, 2021
17.4.3.3 Segmental Revenue/Market Shares, 2021
17.4.4 Product Benchmarking
17.5 Catalent, Inc.
17.5.1 Company Snapshot
17.5.2 Company Overview
17.5.3 Financial Analysis
17.5.3.1 Net Revenue, 2017-2021
17.5.3.2 Regional Revenue/Market Shares, 2021
17.5.3.3 Segmental Revenue/Market Shares, 2021
17.5.4 Product Benchmarking
17.5.5 Strategic Outlook
17.6 CordenPharma
17.6.1 Company Snapshot
17.6.2 Company Overview
17.6.3 Product Benchmarking
17.6.4 Strategic Outlook
17.7 Evonik Industries AG
17.7.1 Company Snapshot
17.7.2 Company Overview
17.7.3 Financial Analysis
17.7.3.1 Net Revenue, 2017-2021
17.7.3.2 Regional Revenue/Market Shares, 2021
17.7.3.3 Segmental Revenue/Market Shares, 2021
17.7.4 Product Benchmarking
17.7.5 Strategic Outlook
17.8 FAMAR Health Care Services
17.8.1 Company Snapshot
17.8.2 Company Overview
17.8.3 Product Benchmarking
17.8.4 Strategic Outlook
17.9 Fresenius Kabi Ag
17.9.1 Company Snapshot
17.9.2 Company Overview
17.9.3 Financial Analysis
17.9.3.1 Net Revenue, 2017-2021
17.9.3.2 Regional Revenue/Market Shares, 2021
17.9.3.3 Segmental Revenue/Market Shares, 2021
17.9.4 Product Benchmarking
17.9.5 Strategic Outlook
17.10 Grifols SA
17.10.1 Company Snapshot
17.10.2 Company Overview
17.10.3 Financial Analysis
17.10.3.1 Net Revenue, 2017-2021
17.10.3.2 Regional Revenue/Market Shares, 2021
17.10.3.3 Segmental Revenue/Market Shares, 2021
17.10.4 Product Benchmarking
17.10.5 Strategic Outlook
17.11 Hikma Pharmaceuticals PLC
17.11.1 Company Snapshot
17.11.2 Company Overview
17.11.3 Financial Analysis
17.11.3.1 Net Revenue, 2017-2021
17.11.3.2 Regional Revenue/Market Shares, 2021
17.11.3.3 Segmental Revenue/Market Shares, 2021
17.11.4 Product Benchmarking
17.11.5 Strategic Outlook
17.12 Jubilant Pharmova Limited
17.12.1 Company Snapshot
17.12.2 Company Overview
17.12.3 Financial Analysis
17.12.3.1 Net Revenue, 2017-2021
17.12.3.2 Regional Revenue/Market Shares, 2021
17.12.3.3 Segmental Revenue/Market Shares, 2021
17.12.4 Product Benchmarking
17.12.5 Strategic Outlook
17.13 Lonza
17.13.1 Company Snapshot
17.13.2 Company Overview
17.13.3 Financial Analysis
17.13.3.1 Net Revenue, 2017-2021
17.13.3.2 Regional Revenue/Market Shares, 2021
17.13.3.3 Segmental Revenue/Market Shares, 2021
17.13.4 Product Benchmarking
17.13.5 Strategic Outlook
17.14 Patheon, Inc. (Thermo Fischer)
17.14.1 Company Snapshot
17.14.2 Company Overview
17.14.3 Financial Analysis
17.14.3.1 Net Revenue, 2017-2021
17.14.3.2 Regional Revenue/Market Shares, 2021
17.14.3.3 Segmental Revenue/Market Shares, 2021
17.14.4 Product Benchmarking
17.14.5 Strategic Outlook
17.15 Pfizer CentreOne
17.15.1 Company Snapshot
17.15.2 Company Overview
17.15.3 Financial Analysis
17.15.3.1 Net Revenue, 2017-2021
17.15.3.2 Regional Revenue/Market Shares, 2021
17.15.3.3 Segmental Revenue/Market Shares, 2021
17.15.4 Product Benchmarking
17.15.5 Strategic Outlook
17.16 Recipharm AB
17.16.1 Company Snapshot
17.16.2 Company Overview
17.16.3 Product Benchmarking
17.16.4 Strategic Outlook
17.17 Siegfried Holding AG
17.17.1 Company Snapshot
17.17.2 Company Overview
17.17.3 Financial Analysis
17.17.3.1 Net Revenue, 2017-2021
17.17.3.2 Regional Revenue/Market Shares, 2021
17.17.3.3 Segmental Revenue/Market Shares, 2021
17.17.4 Product Benchmarking
17.17.5 Strategic Outlook
17.18 Nexus Pharmaceuticals, Inc.
17.18.1 Company Snapshot
17.18.2 Company Overview
17.18.3 Product Benchmarking
17.18.4 Strategic Outlook
17.19 Avara Pharmaceutical Services, Inc.
17.19.1 Company Snapshot
17.19.2 Company Overview
17.19.3 Product Benchmarking
17.20 Eli Lilly and Company
17.20.1 Company Snapshot
17.20.2 Company Overview
17.20.3 Financial Analysis
17.20.3.1 Net Revenue, 2017-2021
17.20.3.2 Regional Revenue/Market Shares, 2021
17.20.4 Product Benchmarking
17.20.5 Strategic Outlook
17.21 Adare Pharma Solutions
17.21.1 Company Snapshot
17.21.2 Company Overview
17.21.3 Product Benchmarking
17.21.4 Strategic Outlook

18 Conclusion and Recommendations
18.1 Concluding Remarks from
18.2 Recommendations for Market Players



★調査レポート[世界の無菌注射剤CMO（受託製造アウトソーシング）市場2022年～2032年] (コード：VGA23FB006)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の無菌注射剤CMO（受託製造アウトソーシング）市場2022年～2032年]についてメールでお問い合わせ

※関連調査レポートはありません。


◆H&Iグローバルリサーチのお客様（例）◆